CCND1基因与乳腺癌和他莫西酚耐药的关系

RELATIONSHIP BETWEEN CCND1 AND TAMOXIFEN RESISTANCE IN BREAST CANCER

乳腺癌是少数对于激素治疗敏感的肿瘤之一,内分泌治疗效果明确;他莫西酚(TAM)是乳腺癌的一线内分泌治疗药物,然而其耐药问题始终困扰着临床医师。CCND1基因是近年来确定的癌基因,在多种人类肿瘤中具有异常表现,与乳腺癌的关系尤为密切,是近年来研究较为深入的基因。目前研究表明:CCND1基因的表达与乳腺癌的发生、相关标记的表达(如雌激素受体ER)、他莫西酚治疗敏感性及预后具有相关性。本文综述CCND1基因与乳腺癌的关系,及CCND1基因与乳腺癌他莫西酚治疗敏感性的关系。对于CCND1基因与乳腺癌关系的研究,有助于理解乳腺癌的发生机制及雌激素在乳腺癌中的作用方式。CCND1基因可能成为乳腺癌基因治疗的新靶点,并在乳腺癌患者的内分泌治疗筛选中起到重要作用。

Breast cancer is one of the few cancers which is sensitive to the hormonal therapy.Till now,tamoxifen is the first line hormonal therapeutic drug to breast cancer,however,drug-resistance is always bothering clinical treatment of breast cancer.CCND1 is recently published oncogen which appears abnormal in many kinds of cancers,especially in breast cancer.From recent clinical trails,there appears to be some relationship between CCND1 and other biomarkers and even the prognosis of beast cancer.In this paper,we review the relationship between CCND1 and breast cancer including tamoxifen responce.The research on CCND1 may contribute to demonstrate the mechanism of breast cancer,the function of estrogen during this process.CCND1 might be a new target in gene therapy,and it may help us to select the proper hormonal therapy for the patients.